Tobramycin

Chemical formula: C₁₈H₃₇N₅O₉  Molecular mass: 467.515 g/mol  PubChem compound: 36294

Therapeutic indications

Tobramycin is indicated for:

Bacterial infections of central nervous system

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Bacterial infection of central nervous system and additionally Tobramycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Gastro-intestinal infections, peritonitis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Bacterial gastrointestinal infectious disease
Peritonitis
and additionally Tobramycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Lower respiratory tract infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Lower respiratory tract infection and additionally Tobramycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Skin, bone and soft tissue infections, burns

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Soft tissue infection
Infection of bone
Burn
and additionally Tobramycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated and recurrent urinary tract infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Urinary tract infectious disease and additionally Tobramycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial infections of central nervous system

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Bacterial infection of central nervous system and additionally Tobramycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Gastro-intestinal infections, peritonitis

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

at least one of
Bacterial gastrointestinal infectious disease
Peritonitis
and additionally Tobramycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Lower respiratory tract infections

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Lower respiratory tract infection and additionally Tobramycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Skin, bone and soft tissue infections, burns

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

at least one of
Soft tissue infection
Infection of bone
Burn
and additionally Tobramycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated and recurrent urinary tract infections

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old)

Urinary tract infectious disease and additionally Tobramycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial infections of central nervous system

Population group: only newborns (0 - 40 days old)

Bacterial infection of central nervous system and additionally Tobramycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Gastro-intestinal infections, peritonitis

Population group: only newborns (0 - 40 days old)

at least one of
Bacterial gastrointestinal infectious disease
Peritonitis
and additionally Tobramycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Lower respiratory tract infections

Population group: only newborns (0 - 40 days old)

Lower respiratory tract infection and additionally Tobramycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Skin, bone and soft tissue infections, burns

Population group: only newborns (0 - 40 days old)

at least one of
Soft tissue infection
Infection of bone
Burn
and additionally Tobramycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated and recurrent urinary tract infections

Population group: only newborns (0 - 40 days old)

Urinary tract infectious disease and additionally Tobramycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Chronic pulmonary infection by Pseudomonas aeruginosa in cystic fibrosis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Tobramycin is indicated for the suppressive therapy of chronic pulmonary infection due to Pseudomonas aeruginosa in adults and children aged 6 years and older with cystic fibrosis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bacterial infection of eye

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Bacterial infection of eye and additionally Tobramycin susceptible species

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Tobramycin is contraindicated in the following cases:

Hypersensitivity to aminoglycosides

Aminoglycoside allergy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2018: TOBRAMYCIN Solution for injection
Summary of Product Characteristics (SPC) 2016: TOBI Podhaler Inhalation powder, hard capsule
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈